Physician profile
Paul A Rusonis
NPI 1922077171
$1,487.06
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $235.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $206.48 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $184.97 | 2019 | |
| Janssen Biotech, INC. | $156.12 | 2019-2020 | |
| Leo Pharma INC. | $136.62 | 2019-2020 | |
| Galderma Laboratories, L.P. | $93.57 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $70.76 | 2019 | |
| Celgene Corporation | $48.12 | 2019 | |
| Kerecis Limited | $37.22 | 2019 | |
| Lilly USA, LLC | $32.94 | 2019 | |
| Janssen Scientific Affairs, LLC | $26.06 | 2019 | |
| Dermira, INC. | $25.00 | 2019 | |
| Aclaris Therapeutics, INC. | $23.18 | 2019 | |
| Mission Pharmacal Company | $22.41 | 2019 | |
| Genzyme Corporation | $20.93 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $19.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rusonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.